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Abstract
Background:  Lysophosphatidylcholines (lysoPCs) are products of phospholipase A2 (PLA2)
enzyme activity, and like the enzyme, have a direct role in toxic inflammatory responses in variety
of organ systems. Paradoxically, reduced plasma lysoPC levels have been noted in sepsis patients
and systemic treatment with lysoPCs is therapeutic in rodent models of sepsis and ischemia. These
observations suggest that elevation of plasma levels of these lipids can actually help to relieve
serious inflammatory conditions. We demonstrate that specific lysoPCs act as uncompetitive
product inhibitors of plasma secreted PLA2 enzymes (sPLA2s), especially under conditions of
elevated enzyme activity, thus providing a feedback mechanism for the observed anti-inflammatory
effects of these compounds.
Methods: Thin layer chromatography and mass spectroscopy were used to estimate total lysoPC
concentration and the relative contributions of different lysoPC species in rat plasma samples.
Kinetic studies of sPLA2 enzyme activity were conducted on these samples ex vivo and on purified
group IA sPLA2 in vitro after addition of specific lysoPC species to the reaction mixture. Enzyme
activity was also measured in plasma samples of rats injected with these same lysoPCs.
Results: Palmitoyl (16:0), stearoyl (18:0) are the most abundant lysoPCs in rat plasma consistent
with other reports. Kinetic studies demonstrated that both were uncompetitive inhibitors of
plasma sPLA2 enzyme activity. In vitro experiments with group IA sPLA2 confirmed the inhibition
and the kinetic properties of these lysoPC species. Decanoyl lysoPC (10:0), which was not detected
in plasma, did not inhibit enzyme activity in vitro. LysoPC injections into normal rats resulted in
"buffering" of plasma sPLA2 activity in a narrow low range, consistent with the activity-dependent
inhibition suggested by the ex vivo and in vitro experiments.
Conclusion: The results may explain the efficacy of lysoPC therapy during periods of elevated
inflammatory activity and further highlight the utility uncompetitive enzyme inhibitors. In this case,
the inhibitor is a product of the enzyme reaction, and therefore represents an example of activity-
driven feedback inhibition.
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Background
Upregulation of circulating phospholipase A2 enzymes,
principally the secreted isoforms (sPLA2s), is associated
with the activity of the innate immune system and a
number of inflammatory disorders [1-4]. Experimental
and correlative studies suggest increased levels of sPLA2s
in the blood contribute to or are predictive of the tissue
destruction that occurs following trauma, heart and lung
disease, local and systemic infections, brain damage, and
autoimmune disorders [4-9]. PLA2 enzyme activity and
the lipid mediators regulated by that activity are directly
linked to a variety of cell death effector mechanisms
including the production of reactive oxygen species (both
directly and via inflammatory cells), excitotoxicity, and
expression of the death receptor family members in a vari-
ety of cells [10-12]. Many of these activities have been
studied relative to the fatty acid branch of PLA2 pathways,
which includes arachidonic acid and its metabolites
(prostanoids, leukotrienes)[13]. The other products of
PLA2 hydrolysis, the lysophosphatides, are also potent
biological mediators but their mechanisms are more enig-
matic and their actions are often contradictory[14]. There
is current interest in lysophosphatidylcholines (lysoPCs)
in particular, as some of these are proposed for treatment
of systemic inflammatory disorders. This suggestion is
based on reports that plasma lysoPC levels are diminished
with the onset of sepsis in human patients [15,16], and in
rodent models of sepsis and ischemia, lysoPC treatment is
an effective therapy [17-21].
In previous studies, we investigated sPLA2 enzyme activity
in plasma of rats and humans because inhibition of this
group of enzymes, and subsequent tissue repair and pro-
tection, is a long-standing goal of pharmacotherapeutics
[22]. Our studies were expedited by the fact that plasma
sPLA2 enzymes will follow Michaelis-Menten kinetics
when incubated with a broad-spectrum substrate, even
though the specific classes of sPLA2s active in plasma are
diverse. This property made it possible to characterize a
peptide inhibitor of sPLA2 activity (called CHEC-9), also
with broad-spectrum activity, as well as demonstrate the
therapeutic potential of sPLA2 inhibition in vivo. CHEC-9
treatment of both traumatic and autoimmune models of
neurodegeneration resulted in significant cytoprotection
and reduction of cell-mediated inflammation [5,6,23].
These results have been supported by other experimental
studies both in and outside of the nervous system. For
example, infusion of sPLA2 substrate-like compounds
reduces circulating sPLA2 activity and also has both neu-
roprotective and anti-inflammatory effects [24]. Con-
versely, transgenic models that express high systemic
levels of group II or group V sPLA2s demonstrate pro-
atherogenic pathologies and exaggerated lung dis-
ease[8,25,26].
Given the therapeutic advantages of sPLA2 inhibition, we
considered the possibility that under certain conditions
the lysoPC product of sPLA2 activity actually inhibits the
enzyme, thus explaining one aspect of the paradoxical
behaviour of these lipids. Product inhibition is a widely
recognized phenomenon in enzymology [27], but one
that has received scattered experimental attention with
respect to regulation of enzyme activity in mammalian
systems in vivo [28,29]. As for sPLA2, product inhibition
of phosphatidylcholine hydrolysis was suggested to occur
in vitro during experiments with venomous group IA
sPLA2 [30,31]. However there were different conclusions
in these studies as to the source of this inhibition. Further-
more, serum albumin binding to lysoPC was suggested to
neutralize its inhibitory activity, a property that might
limit the applicability of the results to systemic therapies
given the sheer abundance of albumin in plasma. In the
present paper, we first documented the principal lysoPC
species in rat plasma relative to each other and to other
abundant plasma lipids using thin layer chromatography
and mass spectroscopy. Then the effects of exogenous lys-
oPCs were studied with plasma sPLA2 activity ex vivo and
with group IA sPLA2 in vitro. Finally, lysoPCs were
injected into rats to determine the influence of elevating
systemic levels of these compounds on circulating sPLA2
activity. The results suggest that the two most abundant
lysoPC species found in plasma are activity-dependent
uncompetitive inhibitors of sPLA2 enzyme activity, even
in the presence of albumin.
Methods
Sources of enzymes
Blood was obtained from the trunk of 32 female Sprague
Dawley rats (200–250 g) after decapitation. Blood sam-
ples were treated with citrate-phosphate-dextrose antico-
agulant (1:10, Sigma), and plasma prepared by
centrifugation after which samples were frozen at -80°
until used. For 16 of these animals, plasma samples were
pooled from 4–6 rats for ex vivo enzyme assays. The other
16 rats received lysoPC treatments (see below). The Insti-
tutional Animal Care and Use Committee of Drexel Uni-
versity College of Medicine approved all specific
procedures of this study. Purified group IA secreted phos-
pholipase A2 from the venom of the Mozambique spit-




Lipids were extracted from plasma samples using the
Folch method[32] and total phospholipids (PL) were
determined[33]. Samples were mixed with a fixed amount
of insect derived. N-Acetyl-L-erythro-sphingosine ("inter-
nal ceramide", from Sigma) as a control, dried under
nitrogen and re-suspended in chloroform before spottingJournal of Inflammation 2008, 5:17 http://www.journal-inflammation.com/content/5/1/17
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on Merck 5631 TLC plates. The plates were developed in
3 directions with drying between each migration[34]. Sol-
vents for the first and second migration were 1) 60:30:8:2,
chloroform: methanol: formic acid: H20, and 2)
50:40:7:3, chloroform: methanol: 28% ammonium
hydroxide, respectively. For the third migration the plates
were developed in diethyl ether. After development, the
plates were immersed in 10% CuSO3 and 8% H3PO4 solu-
tion for 20 seconds, and charred at 180°C for 20 min [35].
The total intensity of charred spots (area × mean optical
density) was determined with Image J (public domain
software) and values were compared to standard curves
(Fig. 1B) obtained with authentic standards from Avanti
Polar Lipids (Alabaster, AL).
Mass Spectroscopy
Samples from the Folch-extracted lipid were dried and re-
dissolved in chloroform-methanol-300 mM ammonium
acetate in water (60:133:7, v/v/v). Lysophosphatidylcho-
lines were analyzed by electrospray ionization triple
quadrupole mass spectrometry at the Kansas Lipidomics
Research Center, as previously described[36].
Enzyme assays
Enzyme assays were conducted as in previous studies [23]
using a Victor 3 fluorescent reader (Perkin Elmer,
Waltham, MA). The substrate was 1-palmitoyl-2-pyrene-
decanoyl phosphatidylcholine ("10-pyrene"), Caymen
Chemical, Ann Arbor MI) a substrate for all calcium
dependent PLA2s with the exception of cPLA2 and PAF-
AH (LP-PLA2). Substrate solutions were prepared in reac-
tion buffer consisting of 50 mM tris (pH = 7.4), 0.1 M
NaCl, 2 mM CaCl2, 0.25% fatty acid-free albumin. The
substrate forms phospholipids vesicles in this solution
[37], and upon hydrolysis, releases fluorescent 10-
pyrenyldecanoic acid (PDA). Plasma samples were 10%
final and mixed with lysoPCs by gentle shaking for 100
sec, or they were derived from lysoPC-injected rats. All
enzyme reactions were initiated with the addition of the
substrate solution to the sPLA2 containing samples.
Kinetic parameters including the properties of lysoPC
inhibitors were determined by recording the initial maxi-
mum velocities (Vo) of enzyme reactions, obtained
within 2 minutes of initiation. A detailed presentation of
the calculations used in our kinetic analysis has been pre-
sented [23]. Relative fluorescent units (RFU) were con-
verted to product concentration using a standard curve
made with pyrenyldecanoic acid (Invitrogen, Eugene,
OR). Individual reactions were carried out in duplicate or
triplicate and kinetic curves were produced using at least 6
substrate concentrations, with lysoPC or its vehicle (PBS
with 8% ethanol). Representative Lineweaver-Burk and
Michaelis-Menten plots as well as nonlinear regression
analyses are presented in Results. Experiments were
repeated at least 4 times with similar results. Statistical
analyses were by the Mann-Whitney test or Welch test for
the in vivo data since control data for the latter was Gaus-
sian with a variance that was significantly different from
the experimental samples. These calculations, and Km,
Vmax and R2 were made with statistical (INSTAT) and
regression software (Prism), both from Graphpad (San
Diego, CA).
LysoPC treatment of rats
Rats were injected subcutaneously under the loose skin at
the shoulders with synthetic stearoyl (n = 4) or palmitoyl
(n = 4) lysoPCs (25 mg/kg) two hrs before sacrifice and
compared to vehicle-injected rats (n = 8). The relative con-
centrations of active sPLA2 enzymes were measured in
plasma samples of these animals by determining the total
hydrolysis of substrate in 1 hr.
Results
Plasma lysophosphatidylcholines
The two-dimensional thin layer chromatography proce-
dure we adapted was developed to reveal several of the
most abundant phospholipid and sphingolipid species
on a single TLC plate [34] (Fig. 1A). Phosphatidylcholine,
sphingomyelin and lysophosphatidylcholine, were the
major phospholipids appearing on the plates with plasma
samples. Ceramides, cholesterol, free fatty acids, and
phosphatidylinositol also appeared in significant quanti-
ties while lower levels of phosphatidylethanolamine and
galactoceramide were found with this procedure. There-
fore, these plates showed that lysoPCs were a significant
proportion of the lipid component of blood plasma in
rodents and humans, as reported by others [16,38-43].
However, published reports or calculations made from
published reports provide a fairly wide range of estimates
of the total lysoPC concentration in plasma (145 to 270
μM). Our estimates of total lysoPC, including from stand-
ard curves generated on the TLC plates (Fig. 1B), were
207.5 ± 44 μM (TLC, n = 3) and 196 ± 64 μM (mass spec-
troscopy, n = 3). Mass spectroscopy analysis also showed
that palmitoyl (16:0) and stearoyl (18:0), calculated as
mol percent of total lysoPC present, were the most abun-
dant species in plasma, followed by linoleoyl (18:2), and
oleoyl (18:1) lysoPCs, in general agreement with the pre-
vious studies cited above, and similar for rats and humans
(Figs. 1C, D).
Inhibition of sPLA2 activity
Plasma
The possibility that there are endogenous sPLA2 inhibi-
tory factors in plasma was suggested in a previous study
because spontaneous inhibition of the enzyme reaction
was observed in plasma samples as the concentration of
substrate was increased [23]. At these points of higher
activity, the fit to a classic hyperbolic function had deteri-
orated. In the present study therefore, we attempted toJournal of Inflammation 2008, 5:17 http://www.journal-inflammation.com/content/5/1/17
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Lysophosphatidylcholines in rat plasma Figure 1
Lysophosphatidylcholines in rat plasma. (A.) Thin layer chromatography showing the lysoPC spot relative to other abun-
dant plasma lipids. Abbreviations: Cer-ceramide; Galcer- galactoceramide; PC- phosphatidylcholine; PE- phosphatidyleth-
anolamine; SM- sphingomyelin; PI- phosphatidylinositol. Chol- free cholesterol; FFA- free fatty acids; LysoPC- 
lysophosphatidylcholine. InCer- internal control. (B.) Standard curve prepared with a mixture of lysoPCs 16:0, 18:0, and 18:1 
showing semi-quantitative nature of TLC method (see text). Total intensity of the lysoPC spots at different concentrations 
were normalized to the intensity of the internal control spot (Incer) developed on the same plate. (C.) Mol percent of individ-
ual species of lysoPCs in the samples calculated from mass spectra of plasma lipid extracts relative to total lysoPC present in 
the samples. Note that in rat, as described for human, lysoPCs 16:0 and 18:0 are the most abundant species found in 
plasma[16,39]. Inset: Typical MS spectra from plasma lipid extract showing identified lysoPC species and internal standards 
(i.s.). m/z = mass/charge ratio.Journal of Inflammation 2008, 5:17 http://www.journal-inflammation.com/content/5/1/17
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minimize the contribution of endogenous factors by
using plasma samples and substrate concentrations where
the enzyme reaction still followed Michaelis-Menten
kinetics (Table 1). Under these conditions, the influence
of endogenous inhibitory factors was expected to be small
(see also below). We tested the effects of adding lysoPCs
18:0 and 16:0 to these plasma samples prior to initiating
the enzyme reaction. We used synthetic LysoPCs to be cer-
tain of the fatty acid composition and therefore the purity
of the species tested. Both 18:0 and16:0 lysoPCs showed
consistent inhibition of sPLA2 activity (Fig. 2). These data
showed that the extent of the inhibition depended on
substrate concentration and therefore was likely to be
uncompetitive. The kinetic data derived from the regres-
sion analysis of the Michaelis-Menten curves confirmed
this, showing reductions in both Vmax and Km, the defin-
ing feature of uncompetitive inhibition (Table 1).
Group IA sPLA2
Plasma is a complex fluid and therefore presents endless
possibilities for non-specific or unexpected interactions
with the enzyme reactants. Therefore, we repeated the
above experiments in vitro using potent venomous group
IA sPLA2. The purpose of these experiments was also to re-
examine product inhibition of sPLA2 activity, especially
in relation to albumin concentration, already reported for
group IA sPLA2[30,31]. The possibility of endogenous
inhibition in these reactions was examined first with ele-
vated concentrations of substrate. It is important to note
that one product of reactions with the 10-pyrene substrate
is palmitoyl lysoPC which is a potential inhibitor. In fact,
Vo declined at the highest substrate concentrations result-
ing in kinetic curves that showed the best fit to a third
order polynomial (R2 = 0.9821) rather than a hyperbolic
function (Fig. 3A). These complex kinetics and the fall off
of activity could have been due to product inhibition. In
order to test this proposition further, we again took the
approach of reacting the enzyme with a lower range of
substrate concentrations (where the activity still followed
Michaelis-Menten kinetics) but with added lysoPCs (Fig.
3B). Uncompetitive inhibition was observed with both
the 16:0 and 18:0 species. Representative Michaelis-
Menten plots, obtained for four concentrations of the
lipid, are shown for lysoPC 18:0 (Fig. 3B). Regression
analysis of the data again showed a reduction in Vmax
and Km (Table 2). However, lysoPC 10:0, which was not
detected in plasma and therefore was a lipid class specific
control, failed to show inhibition tested under conditions
that gave maximal inhibition with the other lysoPC spe-
cies (i.e. 40 μM lysoPC, 30 μM substrate, Table 2).
Albumin influences
Albumin binding by the lysoPCs may influence some of
their biological activities (see Discussion), but of special
interest in the present study was the possibility that albu-
min also neutralizes group IA sPLA2 product inhibition in
vitro  [30,31]. In the present ex vivo experiments with
plasma, significant inhibition sPLA2 activity was observed
even though albumin is major constituent of plasma
(approximately 3% or ~400 μM) [44]. Since one albumin
molecule can bind two lysoPC molecules [30], and given
the estimated concentrations of lysoPCs in plasma (see
above), it appears that all lysoPC molecules with a pro-
pensity for albumin binding could be bound. It is sug-
gested therefore that albumin does not influence lysoPC
inhibitory activity at least under physiological conditions.
We observed attenuated inhibition of group IA sPLA2
with albumin, but only after preincubation of 40 μM lys-
oPC 18:0 with a large excess of this protein (5% which is
> 600 μM). In these cases, the percent inhibition (i.e., the
percent reduction in Vo) was 29.3 ± 1.6% (n = 4) com-
pared to 63 ± 6% (n = 8) with standard buffer (p < 0.01).
This difference was significant (p = 0.029).
LysoPC treatment of rats
Palmitoyl and stearoyl lysoPCs also regulated plasma
sPLA2 activity 2 hrs after subcutaneous injections in rats
(25 mg/kg). The approach to these studies was similar to
that taken for the in vitro and ex vivo experiments since it
was necessary to limit endogenous mechanisms of inhibi-
tion to interpret the results. Restraint and pre-measure-
ment of activity, and/or experimentally elevating activity
in individual rats, influenced the endogenous inhibitory
Lineweaver-Burk double reciprocal plots illustrating the  kinetics of plasma sPLA2 activity in the presence of lysoPCs  16:0 and 18:0 Figure 2
Lineweaver-Burk double reciprocal plots illustrating 
the kinetics of plasma sPLA2 activity in the presence 
of lysoPCs 16:0 and 18:0. Plots are from ex vivo experi-
ments with plasma. More inhibition (larger differences in 1/V) 
was found with added lysoPCs (20 μM) as the substrate con-
centration was increased (smaller 1/[S]). LysoPC treatment 
also reduced Km (increase in the absolute value of the x 
intercept). These kinetic parameters were also calculated by 
nonlinear regression of Michaelis-Menten functions and con-
firm the uncompetitive character of the inhibition (Table 1).Journal of Inflammation 2008, 5:17 http://www.journal-inflammation.com/content/5/1/17
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mechanisms that were being studied [23]. In such cases,
we were not successful in distinguishing between endog-
enous and exogenous inhibition, a pitfall that was not
unexpected for experiments with naturally occurring
uncompetitive inhibitors. Therefore, measurements were
made on lightly restrained vehicle-injected rats and
showed a typical range of enzyme activities that were com-
pared to those obtained from lysoPC- treated rats. Follow-
ing lysoPC treatment, the range of sPLA2 activities was
significantly lower and narrower than in control rats (Fig.
4). This restriction of enzyme activity was consistent with
the uncompetitive inhibition demonstrated above.
Discussion
The principal finding of this study is that the two most
abundant lysoPC species in plasma are capable of inhibi-
tion of plasma sPLA2 activity. We documented this inhi-
bition ex vivo and in vivo with plasma samples from rats
after treatment with palmitoyl or stearoyl lysoPC species.
The fate of these exogenous lysoPCs after they were added
to the plasma or injected into the animals is uncertain. It
is likely that they ultimately reside in one or more of the
functionally available pools of lysoPC, either free, micel-
lar, bound to LDL or serum proteins such as albumin or
immunoglobulin (anti-phospholipid-immune com-
plexes). The relative abundance of these forms and of the
total lysoPC concentration in plasma is expected to be
highly regulated, including by the balanced activity of
Table 1: Kinetic data for lysoPC inhibition of sPLA2 activity in plasma
Plasma Treatment Vmax (nM/min/ml) Km (μM) R2 Ki ± s.e.m. (μM)
Vehicle 1296 33.24 0.9938
Palmitoyl 684.7 16.12 0.9595 25.9 ± 4.0
Vehicle 1395 27.24 0.9413
Stearoyl 669.2 11.26 0.928 34.2 ± 17.4
Data from enzyme reactions of plasma samples containing lysoPC (20 μM) or vehicle. The reactions for each lysoPC–containing sample were run 
side by side with vehicle-containing samples and they were drawn from the same pool of plasma. In each case the lysoPC reduced both Km and 
Vmax showing the inhibition was uncompetitive. Average Ki values with s.e.m. were calculated as in previous studies from all reactions with 
substrates above 15 μM [23]. R2 = fit to Michaelis-Menten function.
LysoPC inhibition of group IA sPLA2 activity Figure 3
LysoPC inhibition of group IA sPLA2 activity. (A.) Relationship between substrate concentration and velocity in reac-
tions of group IA sPLA2 in the presence of high levels of substrate but without inhibitor. The data suggested there was endog-
enous inhibition at the highest substrate concentrations as the plot deviated from the typical hyperbolic curves shown in B. (B.) 
Plots of Vo versus substrate concentration for group IA sPLA2 activity in the presence of different concentrations of lysoPC 
18:0. In this lower range of substrate concentrations, typical hyperbolic curves were obtained. Note that progressive inhibition 
of activity was found up to 40 μM lysoPC. All reactions were with 15 nM sPLA2. The kinetic parameters for these reactions 
calculated by nonlinear regression are shown in Table 2: PDA-pyrenyldecanoic acid.Journal of Inflammation 2008, 5:17 http://www.journal-inflammation.com/content/5/1/17
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sPLA2s and lysophosphatidylcholine acyltransferases
[45], enzymes that cleave and attach the A2 fatty acid.
Despite these uncertainties as to the fate of the exogenous
lysoPCs, it appears that a 10–20% increase in their total
molar concentration in plasma is sufficient to inhibit
sPLA2 activity ex vivo. In addition, the fact that we used a
general sPLA2 substrate further suggests these lysoPCs
have the potential to inhibit several of the sPLA2 isoforms
found in plasma [46,47].
Uncompetitive inhibitors are ideal for in vivo applications
because they are most effective during periods of elevated
enzyme activity, but do not necessarily respond to normal
levels of activity [23,48,49]. These inhibitors bind the
enzyme-substrate complex (ES), and for sPLA2 enzymes,
levels of this complex are highest during periods of
inflammatory stress [23]. Since there are presumably high
levels of lysoPC product at this time, all the elements
required to optimize uncompetitive inhibition are well
represented as the sPLA2-driven inflammatory response
proceeds. This uncompetitive property of the inhibition
also suggests the biomolecular configuration of the inhib-
itory complex, i.e., where this inhibition is likely to occur.
Assuming the enzyme "scoots" along the surface of circu-
lating phospholipid (PL) particles [50], it is suggested that
the lysoPC inhibitor attacks the substrate at points of
advancing enzyme activity (Fig. 5). It would be at these
points that enzyme, substrate, and lysoPC inhibitor are
adjacent and could form the enzyme-substrate-inhibitor
(ESI) complex. The lysoPC involved in the inhibition
could come from the hydrolysis of PC containing particles
("desorbed" lysoPC) [51], free, or albumin-bound lysoPC
in the circulation (see below), or from exogenous sources
as in our experiments.
The pro-inflammatory effects of lysoPCs have been well
documented, both as exogenous agents of toxicity and as
products of sPLA2 hydrolysis. For example, the contribu-
tion of lysoPCs to atherosclerotic lesions is a prime exam-
ple of ability of sPLA2 enzyme activity to direct a local
injurious inflammatory response. LysoPC has been con-
sidered a principal agent of this activity [52,53]. In the
nervous system, exogenous lysoPCs are used in demyeli-
nation studies and as a trigger for responses of the innate
immune system in order to model neuroinflammatory
disorders [54]. Glutamate toxicity after cerebral ischemia
Table 2: Kinetic data for lysoPC inhibition of group IA sPLA2
[LysoPC] μM Vmax (μM/min/ml) Km (μM) R2 Ki ± s.e.m. (μM)
Stearoyl
Vehicle 305.8 17.12 0.993 n.c.
10 221.9 9.37 0.959 n.c.
20 156.2 5.92 0.808 n.c.
40 92.15 7.31 0.949 14.46+1.15
Decanoyl
Vehicle  355.7 23.76 .984 -----
40 342.4 25.00 .979 -----
The kinetic parameters for enzyme reactions containing 0–40 μM lysoPC 18:0 (stearoyl), and 15 nM group IA sPLA2 (see Fig. 3). Vehicle = no 
lysoPC. As the concentration of lysoPC increases Vmax is reduced. This result, along with the consistent reduction in Km, demonstrated that the 
inhibition was uncompetitive. The Ki value was calculated for 40 μM lysoPC only and from reactions with substrates above 15 μM (n.c. = not 
calculated). R2 = fit to Michaelis-Menten function. No inhibition was found after addition of 40 μM lysoPC 10:0 (decanoyl) to the reactions 
containing 30 μM substrate when compared to vehicle controls reacted at the same time.
LysoPC treatment of normal rats Figure 4
LysoPC treatment of normal rats. Twelve rats were 
treated with subcutaneous injections of 0.25 mg/kg lysoPC in 
PBS containing 8% ethanol or PBS-ETOH vehicle only. The 
rats experienced mild restraint during the injections. Two 
hours later, the rats were sacrificed and plasma sPLA2 activ-
ity was measured by determining the amount of pyrenyldeca-
noic acid (PDA) generated from the 10-pyrene substrate in 
one hour. A typical spread of enzyme activities was seen in 
the vehicle-treated rats while lysoPC treatment produced a 
range of activities that were significantly narrower and lower. 
* = p < 0.05, Welch test.Journal of Inflammation 2008, 5:17 http://www.journal-inflammation.com/content/5/1/17
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is exaggerated by local infusion of lysoPC [55], an effect
attributed to the "detergent action" of the lipid [56]. In the
plasma however, where most lysoPCs are bound to albu-
min [39,43,57], it is assumed that endogenous lysoPCs
are much less toxic, perhaps because of this binding [58].
Our data indicate that at physiological concentrations,
albumin does not effect lysoPC inhibition of plasma
sPLA2 activity ex vivo or in vivo. Considering these results
and the model presented above, it is can be suggested that:
1) albumin binding does not effect the binding to PC con-
taining particles and subsequently the ability of the lys-
oPC to inhibit enzyme activity, or that 2), in some
situations the affinity of the lysoPC for these particles is
stronger than it is for albumin. The latter condition has
been suggested to occur for oxidized low density lipopro-
tein (ox-LDL) particles both normally and during certain
pathologies [57,59]. One interesting possibility is that the
affinity of the PC-containing particles for lysoPCs is regu-
lated by sPLA2 activity; for example, as activity is
increased, the concentration of desorbed lysoPCs also
increases, making the particles more receptive to incorpo-
rating the lysoPC product, which in turn limits enzymatic
activity. The present results suggest that exogenous lys-
oPCs also increase this affinity, thereby accomplishing
sPLA2 inhibition and cytoprotection. In this circumstance
however, the potential toxicity of excess lysoPCs cannot
be ignored, so there is likely an upper limit of lysoPC dos-
ages that will accomplish the inhibition without cytotox-
icity. Dose limitations of synthetic lysoPCs have been
demonstrated for treatment of rodent endotoxaemia [17].
Along these same lines, the bactericidal properties of
sPLA2s suggest a similar constraint exists regarding the
extent of enzyme inhibition tolerated in models of fulmi-
nate bacterial infections [60].
The present results may complement recent studies that
explore other mechanisms for the anti-inflammatory
activities of lysoPCs. For example, the experiments of
Chen, et al [20] showed the specific influence of LysoPC
18:0 on pro-inflammatory HMGB1 release from mono-
cytes and macrophages. Although this effect appears par-
tially mediated by the G2A receptor, we suggest that the
well-known relationship between sPLA2 activity and mac-
rophage activity is also relevant, especially because of the
late stage at which the lysoPC was administered
[2,45,61,62]. It is expected that during this late period, the
cascading inflammatory response would make conditions
ideal for uncompetitive product inhibition of sPLA2 and
resulting attenuation of monocyte/macrophage func-
tions. Likewise, there is substantial cross talk between
sPLA2 enzymes and the activity of pro-inflammatory
cytokines that have been implicated in sepsis models [17].
The suggestion that lysoPC 18:0 also enhances microbial
elimination during sepsis induced by cecal ligation and
puncture [18] might reflect direct effects of the lysoPCs on
bacterial sPLA2 enzymes, since bacterial sPLA2s with
remarkable similarities to the mammalian enzymes have
now been characterized [63]. Finally, the diminished Lys-
oPC/PC (product/substrate) ratio found in sepsis patients
that are more likely to recover [16] is entirely consistent
with inhibition of sPLA2 activity described here. The inhi-
bition might slow the inflammatory cascade and increase
the probability of recovery.
Conclusion
The diverse, sometimes contradictory properties of Lys-
oPCs suggest that the different functional forms of this
class of lipids are highly regulated in the plasma. Under
conditions of severe inflammatory stress and subsequent
elevation of plasma sPLA2 activity, systemic lysoPCs will
help to shift the balance towards sPLA2 inhibition and
Schematic illustrating albumin bound and free LysoPCs rela- tive to circulating phosphatidylcholine (PC)-containing parti- cles and sPLA2 enzymes Figure 5
Schematic illustrating albumin bound and free Lys-
oPCs relative to circulating phosphatidylcholine 
(PC)-containing particles and sPLA2 enzymes. 
According to current theory, the sPLA2 enzyme "scoots" 
along the PC vesicle cleaving the A2 fatty acid to produce lys-
oPC (see text). The desorbed or free lysoPC may be toxic 
and but this toxicity is neutralized by albumin binding. It is 
suggested that when excessive lysoPCs are produced during 
periods of high enzyme activity, they become sPLA2 enzyme 
inhibitors acting at the point of advancing PC hydrolysis. This 
configuration would allow for the formation of the Enzyme-
Inhibitor-Substrate (ESI) complex, a feature of the uncom-
petitive inhibition demonstrated in this study. Exogenous lys-
oPCs may augment this process. It is unclear whether the 
lysoPC acting as an inhibitor is bound to albumin, but in the 
present experiments, physiological concentrations of albumin 
had no discernable effect on the inhibition.Journal of Inflammation 2008, 5:17 http://www.journal-inflammation.com/content/5/1/17
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cytoprotection. LysoPC therapies are therefore possible if
these lipids are introduced systemically at the appropriate
levels and at the appropriate point in the inflammatory
cascade.
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